In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D

Author:

Protić Sara1,Kaličanin Nevena2,Sencanski Milan3ORCID,Prodanović Olivera4,Milicevic Jelena3,Perovic Vladimir3ORCID,Paessler Slobodan56,Prodanović Radivoje1ORCID,Glisic Sanja3

Affiliation:

1. University of Belgrade-Faculty of Chemistry, Studentski trg 12, 11000 Belgrade, Serbia

2. University of Belgrade-Institute of Chemistry, Technology and Metallurgy, Njegoševa 12, 11000 Belgrade, Serbia

3. Laboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia

4. University of Belgrade-Institute for Multidisciplinary Studies, Kneza Višeslava 1, 11030 Belgrade, Serbia

5. Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA

6. Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA

Abstract

Finding an effective drug to prevent or treat COVID-19 is of utmost importance in tcurrent pandemic. Since developing a new treatment takes a significant amount of time, drug repurposing can be an effective option for achieving a rapid response. This study used a combined in silico virtual screening protocol for candidate SARS-CoV-2 PLpro inhibitors. The Drugbank database was searched first, using the Informational Spectrum Method for Small Molecules, followed by molecular docking. Gramicidin D was selected as a peptide drug, showing the best in silico interaction profile with PLpro. After the expression and purification of PLpro, gramicidin D was screened for protease inhibition in vitro and was found to be active against PLpro. The current study’s findings are significant because it is critical to identify COVID-19 therapies that are efficient, affordable, and have a favorable safety profile.

Funder

Science Fund of the Republic of Serbia

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3